A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen

Inclusion Criteria Patients must have: HIV-1 seropositivity. Absolute number of T4 cells 100-300 cells/mm3. Given informed consent. Zidovudine (AZT) therapy for 6 months prior to study entry. At least one of the listed HIV-related clinical symptoms or opportunistic infections: weight loss > 10 percent, unexplained diarrhea, unexplained intermittent fever, oral candidiasis > 1 month, decreased Karnofsky, oral hairy leukoplakia, chronic fatigue. Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: Evidence of AIDS. Intercurrent acute medical disorder. Concurrent Medication: Excluded: Chemotherapy for Kaposi's sarcoma (KS). Aspirin. Non-steroidal anti-inflammatory drugs. Patients with the following are excluded: Inability to return for treatment and evaluation for 12 months. Intercurrent acute medical disorder. Evidence of AIDS. Receiving chemotherapy for Kaposi's sarcoma (KS). Unwilling or unable to give informed consent. Required: Zidovudine (AZT). Required at least 6 months prior to study entry: Zidovudine (AZT). Active drug abuse.